Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the advent of more potent ALK inhibitors and the treatment of ALK-positive lung cancer patients with crizotinib.

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть